AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...
GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...
The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...
Nov. 6, 2024 — Researchers have developed AI-driven mobile robots that can carry out chemical synthesis research with extraordinary efficiency. Researchers show how mobile robots that use AI ...
GlobalData on MSN6d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
Our policy and public affairs colleagues analyse what Chancellor Rachel Reeves' announcement means for the chemical sciences sector in the UK. The RSC and 37 other organisations have signed a letter ...
The ACS Scholars Program awards renewable scholarships to undergraduate students from historically underrepresented groups in the chemical sciences, majoring in chemistry-related disciplines, and ...
The newly approved vaccine, known as Arexvy, represents an advance in preventive health measures, addressing a significant adult demographic at risk from RSV complications. With this approval, Canada ...
And to review, we now have three RSV vaccines that are FDA approved for adults, two protein subunit RSV vaccines, one by Pfizer called ABRYSVO that does not contain an adjuvant, and one by GSK called ...
US clinical-stage drug developer Acumen Pharmaceuticals (Nasdaq: ABOS) has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief ...
Results from the ARC-10 Phase III study of Arcus Biosciences (NYSE: RCUS) and Gilead Sciences’ (Nasdaq: GILD) domvanalimab and zimberelimab combination therapy indicate a significant reduction in ...
Teva Pharmaceutical Industries Ltd. ADR 1.52% $19.75B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback